Elvitegravir-d8

Elvitegravir-d8 is deuterium labeled Elvitegravir. Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively.

Product Specifications

Product Name Alternative

GS-9137-d8; JTK-303-d8; D06677-d8

UNSPSC

12352005

Target

HIV; HIV Integrase; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Infection

Solubility

10 mM in DMSO

Smiles

OCC(N1C2=CC(OC)=C(CC3=C(C(Cl)=CC=C3)F)C=C2C(C(C(O)=O)=C1)=O)([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H]

Molecular Formula

C23H15D8ClFNO5

Molecular Weight

455.93

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Shimura K, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) . J Virol. 2008 Jan;82 (2) :764-74.